Tag Archives: AGRX

Maxim Group Keeps Their Buy Rating on Agile Therapeutics (AGRX)

Maxim Group analyst Jason McCarthy maintained a Buy rating on Agile Therapeutics (AGRX – Research Report) yesterday and set a price target of $3. The company’s shares opened today at $1.33. McCarthy observed: “Agile announced that the FDA has accepted

Agile Therapeutics (AGRX) Gets a Buy Rating from Maxim Group

Maxim Group analyst Jason McCarthy maintained a Buy rating on Agile Therapeutics (AGRX – Research Report) yesterday and set a price target of $3. The company’s shares closed yesterday at $1.41. McCarthy wrote: “Agile Therapeutics announced that the NDA for

A Director at Agile Therapeutics (NASDAQ: AGRX) is Buying Shares

Today, a Director at Agile Therapeutics (AGRX – Research Report), Abhijeet Lele, bought shares of AGRX for $30.8K. Following this transaction Abhijeet Lele’s holding in the company was increased by 111.43% to a total of $57.3K. This is Lele’s first

The CEO of Agile Therapeutics (NASDAQ: AGRX) is Buying Shares

Today, the CEO of Agile Therapeutics (AGRX – Research Report), Alfred Altomari, bought shares of AGRX for $38.5K. Following this transaction Alfred Altomari’s holding in the company was increased by 11.71% to a total of $365K. See today’s analyst top

Maxim Group Sticks to Its Buy Rating for Agile Therapeutics (AGRX)

Maxim Group analyst Caroline Palomeque maintained a Buy rating on Agile Therapeutics (AGRX – Research Report) today and set a price target of $3. The company’s shares opened today at $1. Palomeque commented: “Agile Therapeutics announced topline results from its

Analysts Are Bullish on These Healthcare Stocks: Agile Therapeutics (AGRX), NovaBay Pharma (NBY)

There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Agile Therapeutics (AGRX – Research Report), NovaBay Pharma (NBY – Research Report) and Avenue Therapeutics Inc (ATXI – Research Report) with bullish